Clinical Trial Update: A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of a Shigella vaccine (SF2a-TT15) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigella Infection
• Shigellosis

Drugs mentioned

• SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15)

Snippet

Sponsor: Institut Pasteur | Conditions: Healthy | Phase 2 | Status: COMPLETED